IBIsabelle Benz-De Bretagne

Isabelle Benz-De Bretagne

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Isabelle Benz-De Bretagne has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Monitoring of Intensive Care Patients by a Physiology-Related GFR Method

    by Bertil Kågedal, Jean-Baptiste Woillard, Stephan Ehrmann, Charlotte Salmon-Gandonnière, Isabelle Benz-De Bretagne, Carl-Fredrik Mandenius

    Background: In the intensive care of critically ill patients, accurate and reliable determination of the glomerular filtration rate (GFR) is of utmost importance. We have previously used one of the most established methods for this purpose, iohexol plasma clearance measurement, in combination with a mechanistic model based on mass balances and physiological intercompartmental transport. Here, we apply this method in an intensive care unit setting to investigate its validity for estimating GFR and to interpret data from critically ill patients. Methods: In 86 patients undergoing advanced supportive care for shock, sepsis, or other severe conditions, GFR was estimated using the clearance of iohexol during 24 h after an intravenous injection. Individual iohexol plasma clearance was determined by the mass balance model. Parameters were fitted to each patient’s plasma clearance profiles to estimate GFR. The model estimates were compared with estimations using the established Bröchner–Mortensen regression approach and a maximum a posteriori Bayesian estimator. Results: Iohexol plasma disappearance was stable over the 24-h monitoring period in 80% of patients, while 20% exhibited unstable elimination profiles. In patients with stable profiles, the mechanistic model showed significant correlations with Bröchner–Mortensen estimates and the Bayesian estimator. Conclusion: This physiology-based model strengthens the determination of GFR by providing interpretable parameters linked to transport and exchange processes between plasma and extracellular volumes and urinary excretion. The model shows that short-term GFR changes can be illustrated during the plasma concentration trajectory of iohexol, and short-term GFRs can be calculated.

  • Homocystinuria in a 14-year-old girl with neurodevelopmental delay

    by N. Mureau, F. Chapart, M. Perivier, I. Benz-De Bretagne, M. Tardieu, F. Labarthe, R.K. Khanna, H. Blasco

  • Open Access

    Implication of Central Nervous System Barrier Impairment in Amyotrophic Lateral Sclerosis: Gender-Related Difference in Patients

    by Hugo Alarcan, Patrick Vourc’h, Lise Berton, Isabelle Benz-De Bretagne, Eric Piver, Christian R. Andres, Philippe Corcia, Charlotte Veyrat-Durebex, Hélène Blasco

    Central nervous system (CNS) barrier impairment has been reported in amyotrophic lateral sclerosis (ALS), highlighting its potential significance in the disease. In this context, we aim to shed light on its involvement in the disease, by determining albumin quotient (QAlb) at the time of diagnosis of ALS in a large cohort of patients. Patients from the university hospital of Tours (n = 307) were included in this monocentric, retrospective study. In total, 92 patients (30%) had elevated QAlb levels. This percentage was higher in males (43%) than in females (15%). Interestingly, QAlb was not associated with age of onset, age at sampling or diagnostic delay. However, we found an association with ALS functional rating scale-revised (ALSFRS-r) at diagnosis but this was significant only in males. The QAlb levels were not linked to the presence of a pathogenic mutation. Finally, we performed a multivariate survival analysis and found that QAlb was significantly associated with survival in male patients (HR = 2.3, 95% CI = 1.2–4.3, p = 0.009). A longitudinal evaluation of markers of barrier impairment, in combination with inflammatory biomarkers, could give insight into the involvement of CNS barrier impairment in the pathogenesis of the disease. The gender difference might guide the development of new drugs and help personalise the treatment of ALS.


  • Open Access

    History, extensive characterization and challenge of anti-tetanus serum from World War I: exciting remnants and deceived hopes

    by Nicolas Aubert, Marie Brachet-Botineau, Giulia Emi de Olivera Preto, Isabelle Benz-De Bretagne, Hervé Watier, Guillaume Brachet

    During World War I (WWI), infectious diseases including tetanus were among the most important causes of death. Even though its efficacy was somewhat controversial before the war, tetanus antiserum played a key role in reducing the mortality of this disease. A vial of tetanus antiserum dating back from WWI, left behind on the French battlefield by the US Army, was borrowed from a private collection and opened. The serum contained within was characterized by orthogonal biochemical techniques to determine if any neutralizing IgGs could remain after 100 years of storage. In vitro analysis by Size Exclusion Chromatography and Serum Protein Electrophoresis suggested the presence of residual IgG. In spite of our hopes, these IgGs were not able to protect mice against tetanus toxin challenge in a neutralizing assay. Even though our results indicate the presence of remaining IgGs inside the serum, they were functionally disabled. These results show that obscurity alone is insufficient to protect IgGs from degradation over very long periods of time at room temperature. Highlights Tetanus antiserum found its place in the therapeutic arsenal during World War I A century-old vial of tetanus antiserum was opened for biochemical and in vivo characterization Biochemical assays revealed the presence of proteins having all the characteristics of IgGs The serum was unable to protect mice against toxinic challenge


  • Preanalytical step of urinary protein measurement: from urine sampling to preparation for analysis of the specimen

    by Isabelle Benz-De Bretagne, Franck Perrier, Laurence Piéroni, Elisabeth Plouvier, Elizabeth Caussé

    The preanalytical phase is a key step in urinary protein measurement. It is a complex step, which includes urine sampling, storage and transport to the laboratory and preparation for analysis of the specimen. It can lead to numerous errors, since urine sampling is made by the patient himself. According to different cases, the procedures for urine sampling are presented in appendix 1 to 4. The aim of the presented guidelines is to improve the preanalytical step. In addition to the sampling made by a well-informed patient, the laboratory has to optimize transport and sample preservation, according to the analytes. The 24-hour urine collection is divided into aliquots with commercially available systems. Urinary proteins are measured on samples stored without preservatives. When 24-hour urine collection is not possible, a mid-stream urine sample is the most appropriate sample for protein measurement.